Medications

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Medications

Simeprevir in hepatitis C: Added benefit for certain patients

The drug simeprevir (trade name: Olysio) has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection. In an early benefit assessment pursuant to the Act on the Reform of the Market ...

Medications

Sofosbuvir: Indication of added benefit for specific patients

The drug sofosbuvir has been available since January 2014 as a treatment for chronic hepatitis C infection. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the ...

Diseases, Conditions, Syndromes

Sofosbuvir shows promise for chronic hepatitis C infection

(HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide ...

Diseases, Conditions, Syndromes

Telaprevir: Added benefit in certain patients with hepatitis C

The drug telaprevir (trade name: Incivo) has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for ...

page 1 from 2